Drug intelligence / Profile preview

B007

Development stage: Phase 3
Lead developer: Shanghai Cross-linked Pharmaceutical Research and Development
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

B007 is a recombinant humanized anti-CD20 monoclonal antibody developed by Shanghai Jiaolian Drug Research and Development Co., Ltd. It is administered via subcutaneous injection and is currently being investigated in Phase II/III clinical studies for the treatment of Primary Membranous Nephropathy, Pemphigus, and Generalized Myasthenia Gravis. Its mechanism of action involves targeting the CD20 protein, typically leading to B-cell depletion.

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on B007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B007.

Explore the full profile